Registered outcomes20

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 20

Download this page as JSON

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07541378/registered

API reference For AI assistants

List	Outcome	Time frame	Description
Primary	Endurance time during constant-work-rate cycle ergometry (CWRCE)	Baseline and after 28 days of each treatment period	Change in endurance time (ET) during constant-work-rate exercise testing at 80% peak workload, measured by cardiopulmonary exercise testing (CPET).
Secondary	Peak oxygen uptake (VO₂peak) during CPET	Baseline and after 28 days of each treatment period	Change in peak oxygen uptake measured during cardiopulmonary exercise testing (CPET).
Secondary	Oxygen uptake (VO₂) at isotime during CPET	Baseline and after 28 days of each treatment period	Change in oxygen uptake at isotime measured during cardiopulmonary exercise testing (CPET).
Secondary	Forced expiratory volume in 1 second (FEV₁)	Baseline and after 28 days of each treatment period	Change in forced expiratory volume in 1 second (FEV₁).
Secondary	Forced vital capacity (FVC)	Baseline and after 28 days of each treatment period	Change in forced vital capacity (FVC).
Secondary	Inspiratory capacity at rest during CPET	Baseline and after 28 days of each treatment period	Change in inspiratory capacity at rest measured during cardiopulmonary exercise testing (CPET).
Secondary	Inspiratory capacity at isotime during CPET	Baseline and after 28 days of each treatment period	Change in inspiratory capacity at isotime measured during cardiopulmonary exercise testing (CPET).
Secondary	Inspiratory capacity at peak exercise during CPET	Baseline and after 28 days of each treatment period	Change in inspiratory capacity at peak exercise measured during cardiopulmonary exercise testing (CPET).
Secondary	St. George's Respiratory Questionnaire (SGRQ) total score	Baseline and after 28 days of each treatment period	Change in St. George's Respiratory Questionnaire (SGRQ) total score. Scores range from 0 to 100, with lower scores indicating better health-related quality of life and higher scores indicating worse health-related quality of life.
Secondary	Dyspnoea intensity at isotime measured by the Modified Borg Dyspnoea Scale	Baseline and after 28 days of each treatment period	Change in dyspnoea intensity at isotime measured by the Modified Borg Dyspnoea Scale. Scores range from 0 to 10, with lower scores indicating less dyspnoea and higher scores indicating more severe dyspnoea.
Secondary	COPD Assessment Test (CAT) total score	Baseline and after 28 days of each treatment period	Change in COPD Assessment Test (CAT) total score. Scores range from 0 to 40, with lower scores indicating a better outcome and higher scores indicating a worse outcome.
Secondary	Veterans Specific Activity Questionnaire (VSAQ) score	Baseline and after 28 days of each treatment period	Change in Veterans Specific Activity Questionnaire (VSAQ) score. Scores range from 1 to 13, with higher scores indicating greater exercise capacity.
Secondary	Duke Activity Status Index (DASI) total score	Baseline and after 28 days of each treatment period	Change in Duke Activity Status Index (DASI) total score. Scores range from 0 to 58.2, with higher scores indicating better functional capacity.
Secondary	Dyspnoea intensity at peak exercise measured by the Modified Borg Dyspnoea Scale	Baseline and after 28 days of each treatment period	Change in dyspnoea intensity at peak exercise measured by the Modified Borg Dyspnoea Scale. Scores range from 0 to 10, with lower scores indicating less dyspnoea and higher scores indicating more severe dyspnoea.
Secondary	Modified Medical Research Council (mMRC) Dyspnoea Scale score	Baseline and after 28 days of each treatment period	Change in Modified Medical Research Council (mMRC) Dyspnoea Scale score. Scores range from 0 to 4, with lower scores indicating less dyspnoea and higher scores indicating more severe dyspnoea.
Other	Plasma myostatin concentration	Baseline V1 and after each 28-day treatment period	Evaluation of circulating plasma myostatin levels as a biomarker of muscle metabolism and potential predictor of exercise capacity and treatment response in COPD patients.
Other	Body fat percentage assessed by bioelectrical impedance analysis	Baseline V1 and after 28 days of each treatment period	Change in body fat percentage assessed by bioelectrical impedance analysis performed under standardized conditions.
Other	Fat-free mass assessed by bioelectrical impedance analysis	Baseline V1 and after 28 days of each treatment period	Change in fat-free mass assessed by bioelectrical impedance analysis performed under standardized conditions.
Other	Skeletal muscle mass assessed by bioelectrical impedance analysis	Baseline V1 and after 28 days of each treatment period	Change in skeletal muscle mass assessed by bioelectrical impedance analysis performed under standardized conditions.
Other	Visceral fat level assessed by bioelectrical impedance analysis	Baseline V1 and after 28 days of each treatment period	Change in visceral fat level assessed by bioelectrical impedance analysis performed under standardized conditions.